Key Drivers
- Cash Flow Strength
- Leverage Pressure
- Rich Valuation
AIAI Summary
RDNT should now be viewed as a two-engine growth story—strong imaging execution plus rapidly scaling Digital Health ARR—but the investment case only works if that software growth converts into durable margins before debt and weak EPS conversion start to constrain upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Leverage Pressure
- •Rich Valuation
RDNT generates solid cash flow and improving quarterly margins, but high leverage, weak interest coverage, and a rich valuation make it a hold rather than a clear buy.
Price Behavior
Key Price Behavior Insights:
- •Bullish breakout
- •Strong momentum
- •Key support hold
RDNT has broken above its prior congestion zone and hit a new last month high, with strong momentum still intact but stretched enough to favor a near-term pause unless it holds $72.39 and the $68.16-$69.22 support zone.
Sharp acceleration after 2026-08-03 drove a ~22% rise from the 2026-07-17 close
Sentiment & News
Key News Insights:
- •Record Q2
- •AI momentum
- •Raised guidance
RadNet posted a strong Q2 with record revenue and EBITDA, expanding advanced imaging and Digital Health growth, and raised guidance, though EPS remained below last year.
The beat-and-raise quarter should support sentiment and valuation if RadNet can sustain its advanced imaging and Digital Health growth trajectory
Similar Companies in Healthcare
Other companies in the same sector with AI ratings